ABSTRACT
The research-based pharmaceutical industry is under increasing cost pressure from slowing sales and high drug development costs. Cost pressures are exacerbated because of the need for rapid cost recovery, which creates a need for expensive multicountry development programs. The amount of work involved in a single regulatory submission is increasing. These factors will continue to press the industry to consolidate and force managers of clinical trials to look for new ways to control costs without compromising time or quality.
